All In Biotech

Free tool

FDA Approval Tracker

Original approvals of brand-name drugs and biologics (NDAs and BLAs) and efficacy supplements, which add a new use, population or dose. Approvals by CBER (most vaccines, blood products and cell and gene therapies) are not in Drugs@FDA and so are missing.

Last checked: Nov 20, 2026Latest source record: Aug 28, 2026Drugs@FDA last updated: Nov 18, 2026Methods & limitations

Reset

Matching approvals

25

2023 to 2026

Breakthrough

5

Accelerated

7

Priority review

13

Orphan

20

By year

NDAs and BLAs matching the filters.

  • NDA
  • BLA
View as table
YearNDABLA
202355
202433
202541
202631

25 approvals

Newest first. Hover a badge for what it means.

  • Mimrylo (Rusfertide Acetate) · Takeda Pharms AmAug 28, 2026
    Original approval · NDA 220605NovelPriority reviewOrphanApproval letter

    To treat erythrocytosis in adults with polycythemia vera

  • Zenbexus (Iberdomide Hydrochloride) · Bristol Myers SquibbAug 13, 2026
    Original approval · NDA 221075NovelPriority reviewOrphanApproval letter

    To be used in combination with daratumumab and hyaluronidase-fihj and dexamethasone for adults with multiple myeloma who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent

  • Sarclisa Escena (Isatuximab-Irfc) · Sanofi-Aventis U.S. LLCJul 9, 2026
    Original approval · BLA 761445OrphanApproval letter
  • Beqalzi (Sonrotoclax) · Beone Medicines USAMay 13, 2026
    Original approval · NDA 220711NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat adults with relapsed or refractory mantle cell lymphoma after at least two lines of systemic therapy, including a Bruton's tyrosine kinase inhibitor

  • Komzifti (Ziftomenib) · KuraNov 13, 2025
    Original approval · NDA 220305NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat adults with relapsed or refractory acute myeloid leukemia with a susceptible nucleophosmin 1 mutation who have no satisfactory alternative treatment options

  • Wayrilz (Rilzabrutinib) · Genzyme CorpAug 29, 2025
    Original approval · NDA 219685NovelOrphanApproval letter

    To treat persistent or chronic immune thrombocytopenia that has not sufficiently responded to immunoglobulins, anti-D therapy, or corticosteroids

  • Lynozyfic (Linvoseltamab-Gcpt) · Rengeneron Pharmaceuticals, Inc.Jul 2, 2025
    Original approval · BLA 761400NovelAccelerated approvalPriority reviewOrphanApproval letter

    To treat relapsed or refractory multiple myeloma after at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti CD38 monoclonal antibody

  • Qfitlia (Fitusiran Sodium) · Genzyme CorpMar 28, 2025
    Original approval · NDA 219019NovelOrphanApproval letter

    To prevent or reduce the frequency of bleeding episodes in hemophilia A or B

  • Grafapex (Treosulfan) · MedexusJan 21, 2025
    Original approval · NDA 214759NovelOrphanApproval letter

    For use in combination with fludarabine as a preparative regimen for allogeneic hematopoietic stem cell transplantation for acute myeloid leukemia and myelodysplastic syndrome

  • Alhemo (Concizumab-Mtci) · Novo Nordisk INCDec 20, 2024
    Original approval · BLA 761315NovelPriority reviewOrphanApproval letter

    For routine prophylaxis to prevent bleeding episodes in hemophilia A and B

  • Revuforj (Revumenib Citrate) · SyndaxNov 15, 2024
    Original approval · NDA 218944NovelBreakthrough therapyPriority reviewOrphanApproval letter

    To treat relapsed or refractory acute leukemia

  • Hympavzi (Marstacimab-Hncq) · Pfizer INCOct 11, 2024
    Original approval · BLA 761369NovelOrphanApproval letter

    To prevent or reduce bleeding episodes related to hemophilia A or B

  • Ocrevus Zunovo (Ocrelizumab and Hyaluronidase-Ocsq) · Genentech INCSep 13, 2024
    Original approval · BLA 761371Approval letter
  • Rytelo (Imetelstat Sodium) · GeronJun 6, 2024
    Original approval · NDA 217779NovelOrphanApproval letter

    To treat low- to intermediate-1 risk myelodysplastic syndromes

  • Vafseo (Vadadustat) · AkebiaMar 27, 2024
    Original approval · NDA 215192NovelApproval letter

    To treat anemia due to chronic kidney disease

  • Ryzneuta (Efbemalenograstim Alfa-Vuxw) · Evive BiotechnologyNov 16, 2023
    Original approval · BLA 761134NovelApproval letter

    To treat neutropenia

  • Ojjaara (Momelotinib Dihydrochloride) · GlaxosmithklineSep 15, 2023
    Original approval · NDA 216873NovelOrphanApproval letter

    To treat intermediate or high-risk myelofibrosis in adults with anemia

  • Aphexda (Motixafortide Acetate) · Ayrmid PharmaSep 8, 2023
    Original approval · NDA 217159NovelOrphanApproval letter

    To use with filgrastim (G-CSF) to mobilize hematopoietic stem cells to the peripheral blood for collection and subsequent autologous transplantation in patients with multiple myeloma

  • Elrexfio (Elranatamab) · Pfizer INCAug 14, 2023
    Original approval · BLA 761345NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy

  • Talvey (Talquetamab-Tgvs) · Janssen BiotechAug 9, 2023
    Original approval · BLA 761342NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanApproval letter

    To treat adults with relapsed or refractory multiple myeloma who have received at least four prior therapies

  • Vanflyta (Quizartinib Dihydrochloride) · Daiichi Sankyo INCJul 20, 2023
    Original approval · NDA 216993NovelPriority reviewOrphanApproval letter

    To use as part of a treatment regimen for newly diagnosed acute myeloid leukemia that meets certain criteria

  • Columvi (Glofitamab-Gxbm) · Genentech INCJun 15, 2023
    Original approval · BLA 761309NovelAccelerated approvalPriority reviewApproval letter

    To treat diffuse large B-cell lymphoma, not otherwise specified, or large B-cell lymphoma arising from follicular lymphoma after two or more lines of systemic therapy

  • Epkinly (Epcoritamab-Bysp) · Genmab US, Inc.May 19, 2023
    Original approval · BLA 761324NovelAccelerated approvalPriority reviewOrphanApproval letter

    To treat relapsed or refractory diffuse large B-cell lymphoma (not otherwise specified) and high-grade B-cell lymphoma after two or more lines of systemic therapy

  • Jesduvroq (Daprodustat) · GlaxosmithklineFeb 1, 2023
    Original approval · NDA 216951NovelApproval letter

    To treat anemia caused by chronic kidney disease for adults on dialysis for at least four months

  • Jaypirca (Pirtobrutinib) · Loxo OncolJan 27, 2023
    Original approval · NDA 216059NovelAccelerated approvalPriority reviewOrphanApproval letter

    To treat relapsed or refractory mantle cell lymphoma in adults who have had at least two lines of systemic therapy, including a BTK inhibitor

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.